Holen Sie sich die Stockscreener-App
1.62
0.00%
0.00
Handel nachbörslich:
1.61
-0.01
-0.62%
Schlusskurs vom Vortag:
$1.62
Offen:
$1.6601
24-Stunden-Volumen:
197.32K
Relative Volume:
0.62
Marktkapitalisierung:
$189.29M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.73M
KGV:
-12.46
EPS:
-0.13
Netto-Cashflow:
$-3.92M
1W Leistung:
+10.20%
1M Leistung:
+3.85%
6M Leistung:
+103.29%
1J Leistung:
+80.00%
1-Tages-Spanne:
$1.57
$1.67
1-Wochen-Bereich:
$1.44
$1.67
52-Wochen-Spanne:
$0.6295
$1.91
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
Firmenname
Tiziana Life Sciences Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie TLSA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
1.62 | 171.77M | 0 | -13.73M | -3.92M | -0.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-12-22 | Eingeleitet | B. Riley Securities | Buy |
| 2018-12-17 | Eingeleitet | Laidlaw | Buy |
Tiziana Life Sciences Ltd Aktie (TLSA) Neueste Nachrichten
Is Tiziana Life Sciences Ltd a good long term investmentAccelerated wealth expansion - jammulinksnews.com
Tiziana Life Sciences Ltd Stock Analysis and ForecastDynamic investment growth - jammulinksnews.com
What analysts say about Tiziana Life Sciences Ltd stockRapid wealth accumulation - jammulinksnews.com
Promising Penny Stocks To Watch In July 2025 - Yahoo Finance
Tiziana Life Sciences stock initiated with Buy rating at Lucid Capital Markets - Investing.com Australia
Tiziana Life Sciences (TLSA) Receives Buy Rating with Promising Outlook | TLSA Stock News - GuruFocus
What drives Tiziana Life Sciences Ltd stock priceRapid market gains - jammulinksnews.com
Tiziana Life Sciences reports encouraging results from nasal Alzheimer’s treatment - Proactive financial news
Breakthrough: New Alzheimer's Drug Shows Unexpected Dual ActionFights Inflammation and Amyloid Plaques - Stock Titan
Will Tiziana Life Sciences Ltd stock benefit from interest rate changesFree Predictions - beatles.ru
Is Tiziana Life Sciences Ltd stock a growth or value playFree Financial Group - Newser
What analysts say about Tiziana Life Sciences Ltd stock outlookFree Risk Assessment Services - Newser
Why Tiziana Life Sciences Ltd stock is on top investor watchlistsFree Access to Investment Community - Newser
How Tiziana Life Sciences Ltd stock performs during market volatilityROI Driven Alerts - Newser
What makes Tiziana Life Sciences Ltd stock price move sharplySteady Profit Stock Forecasts - Newser
Why Tiziana Life Sciences Ltd stock attracts strong analyst attentionFree Access to Investors Club - Newser
Multiple Sclerosis Pipeline Landscape Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Tiziana Life Sciences Ltd (TLSA) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Promising Penny Stocks To Consider In June 2025 - simplywall.st
Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting (NASDAQ:TLSA) - Seeking Alpha
Tiziana Life Sciences Adds Fifth Site for Phase 2 Foralumab Trial in Multiple Sclerosis - MarketScreener
Small cap wrap: Tiziana Life Sciences, Challenger Energy, Arrow Exploration... - Proactive financial news
Tiziana expands Phase 2 MS trial to fifth site, commences patient dosing - Proactive financial news
Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center - The Manila Times
Breakthrough Multiple Sclerosis Treatment Enters Next Phase as Weill Cornell Joins Major Clinical Trial - Stock Titan
Market movers: RH, Tiziana, Archer Aviation... - Proactive Investors
Shares of Tiziana Life Sciences (TLSA) Climb on CEO's Upcoming P - GuruFocus
Tiziana shares rise on presentation date for foralumab data - Seeking Alpha
Tiziana CEO to present clinical advances of intranasal foralumab at BIO 2025 - Proactive financial news
Tiziana Life Sciences to Present at the Bio International Convention - The Manila Times
Revolutionary Intranasal Treatment for MS and Alzheimer's: Tiziana CEO Reveals Latest Clinical Findings at BIO 2025 - Stock Titan
Tiziana Life Sciences Ltd (TLSA) Stock: A Comprehensive 52-Week Review - investchronicle.com
Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Up 15.3% – Still a Buy? - Defense World
Finanzdaten der Tiziana Life Sciences Ltd-Aktie (TLSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):